Martin Shkreli was placed in solitary confinement after a report surfaced that the infamous "pharma bro" was using a contraband cellphone to run his pharmaceutical company from prison, according to Forbes.
Mr. Shkreli gained notoriety for inflating the price of a lifesaving anti-infection drug more than fiftyfold. He is serving a seven-year prison sentence for defrauding investors.
The Wall Street Journal reported in March that even from behind bars, Mr. Shkreli continued to call the shots at Phoenixus AG, the rebranded name of his pharmaceutical company.
While incarcerated, Mr. Shkreli reportedly called his handpicked chief executive to fire him, phoned in advice to company officials and tried to buy shares from shareholders.
One source close to Mr. Shkreli's legal team said he was taken to the special housing unit about a week and a half after the article was published. A second source, fellow inmate Justin Liverman, said Mr. Shkreli was moved to solitary confinement.
The Bureau of Prisons told Forbes it would not release information about "an individual inmate's conditions of confinement," but it confirmed that allegations against Mr. Shkreli were being investigated.
Read the full report here.